Zuprevo

Selected form

Tildipirosin

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zuprevo

Property	Description
Active ingredient	Tildipirosin
Form	Solution for injection
Pharmacological class	Macrolide antibiotic
Target audience	Production animals (Cattle and Pigs)
Origin	Semi-synthetic

What Type of Veterinary Medicine is Zuprevo?

Zuprevo is defined as a specialized, prescription-only veterinary antimicrobial agent containing the single active ingredient Tildipirosin, used exclusively in production animals like cattle and pigs. Pharmacologically, Zuprevo is classified as a macrolide antibiotic, belonging to the 16-membered ring macrolides, a structural subgroup confirmed by pharmacological studies. Its designation as a veterinary product reflects its specialized formulation and regulatory approval solely for animal health.

This medication’s general therapeutic purpose is to control bacterial infections by inhibiting the growth of susceptible pathogens. The utility of this compound in managing respiratory illness is clinically recognized, a conclusion supported by its approval status for bovine respiratory disease. This establishes Zuprevo as a trusted option for veterinarians addressing specific bacterial threats in targeted livestock populations.

Composition and Origin of the Active Ingredient

The composition of Zuprevo features the single active ingredient Tildipirosin, presented as a solution for injection. Tildipirosin is defined as a semi-synthetic compound, meaning its structure was chemically modified from the naturally occurring macrolide tylosin, a process intended to optimize its characteristics for veterinary use.

As a single-agent product, the medication is a clear yellowish, sterile liquid. This distinction as a solution for injection allows for precise parenteral delivery, a key differentiating factor from orally administered antibiotics. The base is an aqueous solution containing necessary excipients, such as propylene glycol, to ensure stability and reliable delivery of the active substance.

How Does Tildipirosin Generally Help the Animal?

Tildipirosin provides benefit by interfering with the bacteria's ability to create vital proteins, which effectively stops the bacteria from multiplying and growing. The drug achieves this by selectively targeting the bacterial ribosome, a core component responsible for protein biosynthesis.

This mechanism results in a powerful anti-bacterial effect. The primary goal of this action is to resolve the underlying infection by significantly reducing the pathogen load. Its specific action profile classifies it as both bacteriostatic (stopping growth) and potentially bactericidal (killing) against various susceptible bacteria, meaning the compound is designed both to halt the spread and actively eliminate the invading organisms.

Regulatory References

Zuprevo FDA Freedom of Information Summary

What side effects are possible with Zuprevo?

Possible Side Effects and Safety Information

The official safety profile for Zuprevo (Tildipirosin) is based on regulatory documents from agencies such as the EMA and FDA. Adverse reactions are primarily associated with the administration site, while use is restricted in specific animal populations.

Documented Adverse Reactions

The most frequently observed effects are classified as Very Common (occurring in more than 1 in 10 animals treated).

Species	Frequency	Adverse Reaction (as classified in regulatory documents)
Cattle	Very Common	Injection site reactions, including pain and swelling
Pigs	Very Common	Injection site reactions, including pain and swelling

Serious reactions, though rare, are also documented. Anaphylaxis is classified as a Rare or Very Rare event depending on the species, with regulatory notes indicating a potentially fatal outcome. Certain regulatory documents also report fatal adverse events in swine, leading to specific use prohibitions in some regions.

Safety Restrictions and Limitations

Official labels detail high-level constraints and specific contraindications:

Contraindications: The medicine is contraindicated in animals known to be hypersensitive to macrolide antibiotics or to the product's excipients. It must not be administered simultaneously with other macrolides or lincosamides due to the potential for cross-resistance.
Population Restrictions: The product is not for use in cattle 20 months of age or older that are producing milk for human consumption. Furthermore, the safety of the medicine has not been established for use during pregnancy or lactation. Certain regulatory labels explicitly state: DO NOT USE in swine due to documented safety concerns.
Time-Related Effects: While swelling in pigs is generally transient (resolving within a few days), injection site swelling in cattle may persist for up to 21 days post-treatment, a time-related pattern noted in official safety data.

Overdose and Emergency Response

Overdose and When to Seek Help

The information regarding overexposure to Tildipirosin (Zuprevo) is strictly derived from official government regulatory documents.

Documented Overdose Manifestations

Clinical manifestations observed in cattle and pigs following administration at multiples of the recommended dose are generally reversible and primarily involve the gastrointestinal system and local tissue reactions.

Cattle: Documented signs include temporary appetite loss and transient soft feces at five times the recommended dose. Higher doses have been associated with localized injection site swelling.
Pigs: Signs at five times the recommended dose include localized injection site swelling and temporary diarrhea.

No explicitly documented severe or life-threatening outcomes are reported in the official regulatory documents for the tested overdose levels.

Required Emergency Actions

In the event of a known or suspected overexposure, the official labeling mandates specific immediate actions:

Seek immediate veterinary attention from the prescribing veterinarian or emergency veterinary services. This step is required to assess the severity and initiate management.
Supportive Treatment: Because no specific antidote is known for Tildipirosin, the management of overexposure is limited to providing symptomatic and supportive treatment to address the clinical signs that appear. Close monitoring of the animal may be required.

This profile defines the necessary urgent response based strictly on officially documented clinical presentations and the required management procedures.

Therapeutic Uses of Zuprevo

What Zuprevo Treats: Main Uses and Benefits

Zuprevo is commonly used across conditions presenting with acute episodes to address bacterial infections primarily related to the respiratory tract in production animals. Its therapeutic application is relevant for managing established Bovine Respiratory Disease (BRD) in cattle and is generally applied in addressing Swine Respiratory Disease (SRD). It is applied in clinical settings that involve acute or unstable symptom patterns.

The medication is used to address symptom clusters that interfere with daily functioning, such as high fever, lethargy, and reduced appetite. It is often applied during phases when symptoms become more noticeable, offering supportive relief when symptoms interfere with routine activities.

“This medication is considered relevant for easing symptoms that create noticeable physiological strain in animals suffering from respiratory illness.”

In high-risk scenarios, such as following transport (shipping fever), Zuprevo is employed for metaphylaxis—a strategic intervention in groups of animals deemed to be at risk—which assists with managing the risk of developing full clinical manifestations. This helps maintain a sense of stability and contributes to easing the overall symptom load.

Quick Fact: Relief for Systemic Discomfort

Regulatory References

NIH DailyMed Drug Label

Eligibility and Restrictions for Use

Zuprevo is an antibiotic product approved for veterinary use and is strictly not for human use.

Populations for Whom Use is Prohibited or Restricted

Official regulatory documents define several groups for whom use of this product is contraindicated or prohibited due to safety or residue concerns:

Hypersensitivity: It must not be used in any animal with a known hypersensitivity to macrolide antibiotics or any of the product's excipients.
Non-Target Species: Use is strictly prohibited in swine (due to reported fatal adverse events), chickens, and turkeys.
Dairy Cattle: It is prohibited for use in female dairy cattle 20 months of age or older (including dry cows) due to the risk of drug residues in milk. It is also not authorized for use in animals producing milk for human consumption.
Age Restriction: Use is prohibited in calves to be processed for veal and pre-ruminating calves as a withdrawal period for these animals has not been established.
Drug Interaction: It must not be administered simultaneously with other macrolides or lincosamides due to the potential for cross-resistance.
Breeding Animals: Use is generally not recommended in animals intended for breeding purposes as the effects on reproductive performance, pregnancy, and lactation have not been definitively determined.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Zuprevo (Tildipirosin) as identified in government regulatory documents.

Contraindicated Combinations and Pharmacodynamic Effects

Official regulatory labeling establishes specific restrictions based on Zuprevo’s classification as a macrolide antibiotic. These restrictions are due to an anticipated pharmacodynamic effect known as cross-resistance, where one antibiotic may reduce the effectiveness of another due to shared bacterial targets.

Classification	Interacting Medicinal Products
Formal Contraindication	Other Macrolide antibiotics
Formal Contraindication	Lincosamide antibiotics

Simultaneous administration of Zuprevo with any other macrolide or lincosamide is formally prohibited. This constraint is in place because cross-resistance between these two classes is expected, which could compromise the therapeutic outcome.

Pharmacokinetic and Other Interactions

Regulatory documents do not contain explicit statements concerning several common types of drug interactions, indicating that these effects are not officially documented for Tildipirosin in its approved use:

Metabolic Interactions: There are no official cautions regarding interactions mediated by specific metabolic pathways, such as the cytochrome P450 (CYP) enzyme system.
Transporter Interactions: No information is officially documented concerning interactions involving drug transporters (e.g., P-glycoprotein).
Timing or Separation Requirements: The label does not mandate any specific time intervals between the administration of Zuprevo and other substances; the prohibition applies to simultaneous use of the contraindicated classes.
Food or Supplement Interactions: No interactions with food, alcohol, or nutritional supplements are specified in the official prescribing information.

Mechanism of Action

Molecular Blockade of Protein Biosynthesis

Tildipirosin exerts its action by selectively and reversibly binding to the 50S subunit of the bacterial ribosome . It specifically engages the 23S ribosomal RNA component. This molecular interaction physically blocks the ribosomal exit tunnel, halting the process of peptide chain elongation and inhibiting the synthesis of essential bacterial proteins. This targeted interference results in a bacteriostatic effect (cessation of growth) and, against certain target pathogens, a bactericidal effect (pathogen elimination).

Mechanism of Sustained Local Efficacy

The drug exhibits specialized tissue partitioning, leading to extensive and persistent accumulation within target tissues, particularly the lung and bronchial fluid. This accumulation ensures that the concentrations required to maintain the molecular blockade are held for an extended duration, sustaining the molecular blockade at the site of infection.

Biological Constraints on Mechanistic Efficacy

The function of this mechanism can be constrained by bacterial adaptations. The primary challenge involves methylation of the 23S rRNA binding site, which structurally prevents Tildipirosin from establishing its inhibitory bond. Furthermore, bacterial efflux pump systems can actively expel the molecule from the cell, functionally negating the intended action by preventing the drug from reaching its ribosomal target.

Dosage and Administration Information

Instruction Map: How to use Zuprevo — Official Administration Guidelines

Zuprevo is administered as a single-dose injectable solution for the treatment of production animals. The administration protocol is strictly defined by the animal species and body weight, ensuring the correct delivery and dosage.

Administration Scope

Property	Official Instruction
Route of administration	Cattle: Subcutaneous injection (SC) in the neck. Pigs: Intramuscular injection (IM) behind the ear.
Dosing schedule	A single, standardized dose of 4 mg Tildipirosin per kilogram (mg/kg) body weight (BW).
Special procedural conditions	Cattle over 450 kg: Total dose must be divided, with no more than 10 mL per subcutaneous site. Pigs: Volume should not exceed 5 mL per intramuscular site.

Instruction Classifications (High-Level)

Property	Classification
Administration method type	Parenteral (Subcutaneous/Intramuscular Injection).
Frequency pattern	Once-only use per treatment course (Single Dose).
Use-context constraints	Approved for metaphylaxis (mass treatment of high-risk animals) when the presence of disease in the group is established.

Connection to the overall use protocol

The official instructions define the use of Zuprevo as a single-administration, weight-based treatment requiring strict adherence to both the calculated dosage and the specified anatomical injection site for each species. The protocol mandates volume division for larger animals to maintain proper administration constraints and requires a follow-up evaluation of the animal's clinical response within 2 to 3 days for cattle or 48 hours for pigs.

Recent Clinical Evidence

Overview of Studies for Zuprevo (Tildipirosin)

Evidence for Use in Treating Established Respiratory Disease

Research has primarily focused on the evaluation of Tildipirosin in cattle already showing signs of Bovine Respiratory Disease (BRD), a condition marked by symptoms related to systemic or functional imbalance. The core of the evidence comes from Randomized Controlled Trials (RCTs) conducted in field settings, a design used to assess treatment effects. These studies monitored the rate of treatment success or failure (defined by the need for subsequent medication), changes in clinical signs, and measured rectal temperature. Findings describe patterns observed in these studies, adding to the information available for this area of veterinary medicine.

Evaluation for Disease Control (Metaphylaxis)

Tildipirosin was also evaluated for metaphylaxis, a practice of administering the medicine to groups of high-risk cattle or swine exposed to an outbreak. These placebo-controlled RCTs monitored outcomes like the incidence of BRD and the percentage of healthy animals remaining free of clinical signs during a Swine Respiratory Disease (SRD) outbreak. While studies reported patterns in morbidity and mortality rates, the results apply only to the high-risk populations studied. In some subgroups, findings were mixed regarding secondary outcomes like Average Daily Gain (ADG), indicating that the evidence quality varies across these specific outcomes.

What is Still Uncertain About the Research Evidence

Research has limited insight into long-term outcomes for treated animals beyond the short-term, initial assessment period (often 14 days), meaning durability of the initial response is not fully established. Follow-up durations were limited in many pivotal trials. Furthermore, comparative evidence is lacking for a comprehensive, head-to-head comparison against all other available antimicrobials in a single unified analysis. The evidence base is also highly specific to the defined BRD and SRD indications; research has not explored other types of respiratory conditions.

Key Studies & References ZUPREVO (tildipirosin) solution for injection (Official Drug Label)

Frequently Asked Questions (FAQ)

Common questions about Zuprevo (FAQ)

Q: Is Zuprevo considered a long-term medication?

A: According to official product information, Zuprevo is approved for administration as a single-dose injectable solution per treatment course. This frequency pattern indicates the product is for short-course treatment, rather than ongoing, long-term therapeutic management.

Q: What are the most commonly reported mild side effects of Zuprevo?

A: The most frequently observed effects in treated animals are local injection site reactions, which can include pain and swelling. These are classified in regulatory documents as Very Common, meaning they occur in more than 1 in 10 animals treated.

Q: Are the side effects of Zuprevo generally reversible?

A: Official safety information indicates that injection site swelling in pigs is generally transient, meaning it resolves within a few days. Swelling at the injection site in cattle may persist for up to 21 days post-treatment.

Q: Has Zuprevo been studied in combination with other treatments for the same condition?

A: Regulatory documents formally prohibit the simultaneous administration of Zuprevo with other macrolide or lincosamide antibiotics. The restriction is specified due to the expected potential for cross-resistance between these classes.

Q: Is the efficacy (effectiveness) of Zuprevo different across various patient groups?

A: The evidence for effectiveness is highly specific to Bovine Respiratory Disease (BRD) and Swine Respiratory Disease (SRD). Official research overviews indicate that some subgroups in the studies reported mixed findings regarding certain secondary outcomes, such as Average Daily Gain (ADG).

Q: What makes Zuprevo different from other drugs that treat the same condition?

A: Zuprevo is a macrolide antibiotic delivered via a single-dose parenteral (injection) route. It exhibits specialized tissue partitioning, which helps it accumulate and persist in target tissues like the lung and bronchial fluid. This route of administration is one distinguishing factor described in the official documents.

Q: What is the definition of a 'serious' side effect for Zuprevo?

A: Serious adverse events are documented in the product's safety profile. For example, anaphylaxis is classified as a Rare or Very Rare event, with regulatory notes indicating a potentially fatal outcome.

Q: How quickly should someone expect Zuprevo to start working?

A: Official administration guidance for Zuprevo establishes a time frame for evaluating the clinical response. The protocol requires a follow-up evaluation of the animal's condition within 2 to 3 days after injection for cattle or 48 hours for pigs.

Q: Can Zuprevo cause fatigue or difficulty sleeping?

A: The core adverse reaction tables in regulatory documents do not explicitly list effects like fatigue or difficulty sleeping for the approved species. The safety profile's focus is primarily on local injection site reactions and rare events like anaphylaxis.

Q: Can Zuprevo interact with common pain relievers like ibuprofen or acetaminophen?

A: The official product label for Zuprevo does not contain explicit statements concerning drug interactions involving common pain reliever types. Furthermore, the label does not mandate any specific time intervals for separating the administration of Zuprevo from other non-prohibited substances.

Q: How long does Zuprevo stay in your system after stopping?

A: Information on how the body processes the drug is detailed in regulatory documents. In cattle, the mean terminal half-life of the active ingredient, Tildipirosin, in the plasma is approximately 9 days.

Q: Is Zuprevo known to cause changes in mood or behavior?

A: Regulatory documents list common and serious reactions, such as injection site swelling and anaphylaxis. Effects like changes in mood or behavior are not explicitly listed in the core adverse reaction tables for the approved species.

Q: Does Zuprevo contain any common allergens like gluten or lactose?

A: The official composition of the solution for injection lists the active ingredient Tildipirosin along with excipients. These include propylene glycol, citric acid monohydrate, and water for injections.

Q: Can Zuprevo cause changes in blood pressure or heart rate?

A: Regulatory safety data from studies in laboratory animals examined effects on blood pressure and heart function. At very high doses, the drug was shown to cause minor decreases in pulse pressure and was associated with some changes to heart rhythm markers (ECG changes).

How should Zuprevo be stored and disposed of?

Storage and Disposal of Zuprevo

Zuprevo (tildipirosin) must be stored and disposed of according to its official regulatory labeling to maintain stability and ensure safety.

Storage Requirements

Condition	Requirement
Temperature	Do not store above 30 C (or 25 C, depending on formulation and region) and do not freeze the product.
Post-Opening	The vial must be used within mathbf28 days after the first puncture when stored at or below mathbf25 C.
Child Safety	Keep out of the reach of children.

Disposal Instructions

Unused or expired Zuprevo and its waste materials must be disposed of according to local requirements. The medicine must not be thrown into wastewater or household waste to prevent environmental contamination, as stated in regulatory documents.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.